RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB

VELCADE (bortezomib, PS-341), reversibly inhibits the 20S proteasome and exhibits cytotoxic and antitumor activities. Pretreatment of cancer cells with bortezomib increases the chemosensitivity of these cells, suggesting that bortezomib may be used in combination chemotherapy. The relative contributions of the five major human cytochromes P450 (P450s), 1A2, 2C9, 2C19, 2D6, and 3A4 (the focus of the present study), to the metabolism of bortezomib are an important aspect of potential drug interactions. Relative activity factor (RAF), chemical inhibition, and immunoinhibition using monoclonal antibodies were three approaches employed to determine the relative contributions of the major human P450s to the net hepatic metabolism of bortezomib. RAFs for the P450 isoform-selective substrates were determined; the ratio of the rate of metabolism of bortezomib with cDNA-expressed P450s versus rate of metabolism with human liver microsomes was normalized with respect to the RAF for each P450 isoform to determine the percentage contributions of the P450s to the net hepatic metabolism of bortezomib. CYP3A4 followed by CYP2C19 were determined to be the major contributors to the metabolism of bortezomib. Chemical inhibition and immunoinhibition confirmed that CYP3A4 and CYP2C19 were the major P450s responsible for the hepatic metabolism of bortezomib. The studies were conducted with 2 μM bortezomib, and the disappearance of bortezomib, rather than appearance of a specific metabolite, was quantified to determine the contributions of the P450s to the overall hepatic metabolism of bortezomib in humans.

[1]  Ann Daly,et al.  Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. , 2002, Pharmacogenetics.

[2]  A. Y. Lu,et al.  Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[3]  F. Gonzalez,et al.  Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery. , 1999, Trends in pharmacological sciences.

[4]  B. Rochat.  Evaluation of recombinant cytochromes P450 activity in metabolic pathways. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[5]  A. Y. Lu,et al.  Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[6]  U. Meyer,et al.  Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. , 1997, Pharmacogenetics.

[7]  Michel Roger,et al.  CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS , 2005, Drug Metabolism and Disposition.

[8]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[9]  R. Tyndale,et al.  Inhibition of cytochromes P450 by antifungal imidazole derivatives. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[10]  P. Maurel,et al.  Contribution of human cytochrome P‐450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine , 2003, British journal of pharmacology.

[11]  C. Kettner,et al.  Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids. , 1984, The Journal of biological chemistry.

[12]  O Pelkonen,et al.  Inhibition and induction of human cytochrome P450 (CYP) enzymes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  D. Greenblatt,et al.  Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. , 2001, The Journal of pharmacology and experimental therapeutics.

[14]  M. P. Groziak,et al.  Boron Therapeutics on the Horizon , 2001, American journal of therapeutics.

[15]  K. Korzekwa,et al.  Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. , 2000, European journal of pharmacology.

[16]  G. Lienhard,et al.  2-phenylethaneboronic acid, a possible transition-state analog for chymotrypsin. , 1971, Biochemistry.

[17]  S. G. Waley,et al.  β-lactamase inhibitors. The inhibition of serine β-lactamases by specific boronic acids , 1988 .

[18]  C. Crespi.  Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .

[19]  R. Branch,et al.  Genetic polymorphism of S-mephenytoin hydroxylation. , 1989, Pharmacology & therapeutics.

[20]  P. Elliott,et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.

[21]  M. L. Bender,et al.  Inhibition of serine proteases by arylboronic acids. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Greenblatt,et al.  Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies , 2001, Journal of clinical pharmacology.

[23]  R. Snow,et al.  Boronic acid inhibitors of dipeptidyl peptidase IV: A new class of immunosuppressive agents , 1995 .

[24]  V. Stella,et al.  Degradation pathways of a peptide boronic acid derivative, 2-Pyz-(CO)-Phe-Leu-B(OH)(2). , 2000, Journal of pharmaceutical sciences.

[25]  F. Hsieh,et al.  HUMAN METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB: IDENTIFICATION OF CIRCULATING METABOLITES , 2005, Drug Metabolism and Disposition.

[26]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[27]  L. Dick,et al.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. , 1998, Bioorganic & medicinal chemistry letters.

[28]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[29]  Ron H J Mathijssen,et al.  Modulation of irinotecan metabolism by ketoconazole. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Marie M. Ahlström,et al.  Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.